Published :
Report ID:
Pages :
Format :
Global hospital injectable drugs market revenue was valued at USD 531.8 billion in 2022 to reach USD 1,223.6 billion by 2030, according to a report by the market is projected to grow at a CAGR of 9.05% from 2022 to 2030.
Global Hospital Injectable Drugs Market Overview:
The pharmaceutical sector is growing at a significant rate due to increasing prevalence of the disease, raising awareness and increasing government initiatives. Injectable drugs refer to drugs that are introduced into the patient's body with the help of an injection.
It is injected directly into the bloodstream using injectable devices such as syringes and needles. Based on formulation, the injectables market can be segmented into microspheres, liposomes, and nanoparticles.
North America dominates the global market for hospital injectables due to high demand for pharmaceuticals and technological advancements in the region. Following Asia, Europe is expected to experience high growth rates in the coming years in the global hospital injectables market.
This is due to improved healthcare facilities and increased R&D initiatives in the region. Countries such as Brazil, Russia, China, and India are expected to be the fastest-growing hospital injectables markets. Some of the major driving forces for the hospital injectables market in emerging countries are the large patient pool and rising standard of care in this area.
Awareness and technological advances in this field are driving the global hospital injectables market. Additionally, the improved efficacy demonstrated by this class of drugs, increased prevalence of chronic diseases and improvements in healthcare facilities are driving the hospital injectables market.
However, some of the major factors limiting the global hospital injectables market are stringent government regulations in some countries and lack of experienced healthcare professionals.
The emergence of innovative new drugs such as biosimilars is expected to be a good opportunity for the hospital injection market. Emerging markets also have great growth potential for the hospital injectables market. Side effects and patent expiry of various injectables are challenges facing the hospital injectables market.
Major Market Segments Covered in Hospital Injectable Drugs Market Research:
Market Key Players:Key Vendors:
Baxter International Inc.: Baxter is a global healthcare company that specializes in providing products and therapies for critical care, renal care, medication delivery, and pharmaceuticals. They offer a wide range of hospital injectable drugs, including intravenous solutions, anesthesia drugs, and critical care medications.
Sanofi: Sanofi is a multinational pharmaceutical company that focuses on research, development, manufacturing, and marketing of prescription medications and vaccines. They have a diverse portfolio of hospital injectable drugs, including products for oncology, immunology, infectious diseases, and cardiovascular disorders.
Pfizer Inc.: Pfizer is one of the world's largest pharmaceutical companies, engaged in the development, manufacturing, and marketing of a wide range of medications and vaccines. They offer numerous hospital injectable drugs, including antibiotics, pain management medications, anti-inflammatories, and vaccines.
GlaxoSmithKline plc: GlaxoSmithKline (GSK) is a global healthcare company that specializes in pharmaceuticals, vaccines, and consumer healthcare products. GSK offers hospital injectable drugs in therapeutic areas such as respiratory, oncology, HIV, and vaccines. They also focus on developing innovative drug delivery systems.
AstraZeneca: AstraZeneca is a multinational pharmaceutical company that focuses on the discovery, development, and commercialization of prescription drugs. They have a broad portfolio of hospital injectable drugs, including oncology therapies, respiratory medications, cardiovascular drugs, and anesthesia products.
By Type:
Generic Sterile Injectables: Generic sterile injectables refer to the generic versions of sterile injectable medications. These medications are administered via injections and are required to be sterile to ensure patient safety. Generic sterile injectables are commonly used in hospitals, clinics, and other healthcare settings for various therapeutic indications, such as antibiotics, analgesics, anesthetics, and cardiovascular drugs. These generic versions offer cost-effective alternatives to brand-name sterile injectable medications.
Sterile Intravenous (IV) Solutions: Sterile intravenous solutions are liquid formulations that are administered directly into the veins through intravenous (IV) infusion. These solutions are used to deliver medications, nutrients, or fluids to patients who cannot take them orally or require rapid absorption. Sterile IV solutions are available in various formulations, including saline solutions, dextrose solutions, and electrolyte solutions. They play a critical role in maintaining patient hydration, electrolyte balance, and drug delivery in hospitals and healthcare facilities.
Other: The "Other" category may include additional products or segments related to the hospital injectable drugs market that are not specifically mentioned in the previous categories. This could encompass various injectable products such as contrast agents for imaging procedures, hormone therapies, immunosuppressants, anticoagulants, and other specialized injectables used in specific medical conditions or procedures.
By Application:
Cardiology & Metabolic Disorders: Hospital injectable drugs used to treat heart diseases and metabolic disorders are in this group. It includes drugs like anticoagulants, antiplatelet agents, drugs that lower lipids, drugs that treat high blood pressure, and drugs used to treat diseases like diabetes and obesity.
In neurology, hospital injections of drugs are used to treat conditions like epilepsy, Parkinson's disease, multiple sclerosis, and migraines. These medicines may include drugs that stop seizures, treatments that change the immune system, muscle relaxants, and painkillers.
Oncology: Oncology injectables are an important part of treating many kinds of cancer. These drugs include chemotherapy agents, immunotherapies, targeted therapies, and supportive medicines that help with cancer symptoms and side effects. They are an important part of both curative and supportive care for cancer patients.
Autoimmune: Drugs given by injection in a hospital are used to change the immune reaction and reduce inflammation in people with autoimmune disorders. People who have rheumatoid arthritis, psoriasis, lupus, or inflammatory gut disease take these medicines. Some of them are biologics, immunosuppressants, and disease-modifying antirheumatic drugs (DMARDs).
Gastroenterology: Injectables used in gastroenterology are used to treat stomach and intestine problems like inflammatory bowel disease, Crohn's disease, ulcerative colitis, and stomach and intestine cancers. Some of these drugs are biologics, others are immunosuppressants, and still others are anti-inflammatory drugs.
Hematology: Injectable drugs are used to treat blood problems like anemia, hemophilia, thrombocytopenia, and different types of blood cancer. They include things that help blood clot, things that help cells grow, drugs that change how the immune system works, and chemotherapy drugs that only work on hematological cancers.
Infectious illnesses: Antibiotics, antivirals, antifungals, and antiparasitic drugs can be injected to treat infectious illnesses. They are used to treat many different kinds of illnesses, such as those caused by bacteria, viruses, fungi, and parasites.
Others: The "Others" category may include hospital injectable drugs used for medical conditions or treatments not listed in the other categories. This could include specialized injectables used in critical care, pain control, respiratory disorders, endocrinology, and other areas of medicine.
By End-Use Type:
Based on Region:
North America is the largest market for hospital injectable drugs, accounting for a share of over 35% in 2022. The growth of the market in North America is being driven by the increasing prevalence of chronic diseases, the growing aging population, and the rising demand for personalized medicine.
Europe is the second-largest market for hospital injectable drugs, accounting for a share of over 25% in 2022. The growth of the market in Europe is being driven by similar factors to North America, as well as the increasing focus on patient-centered care.
Asia-Pacific is the fastest-growing market for hospital injectable drugs, accounting for a share of over 10% in 2022. The growth of the market in Asia-Pacific is being driven by the rising prevalence of chronic diseases, the growing aging population, and the increasing economic development in the region.
Latin America and Middle East & Africa are the smallest markets for hospital injectable drugs, accounting for a share of less than 10% each in 2022. The growth of the markets in these regions is being driven by the increasing prevalence of chronic diseases and the rising economic development.
Significant Market Dynamics:
Dynamics
Restraints
Drivers
Trends
Challenges
Opportunities
Scope of Reports:
Report Attribute | Details |
Study Period | 2017-2030 |
Base Year | 2022 |
Estimated year | 2023 |
Forecast period | 2023-2030 |
Historic Period | 2017-2022 |
Units | USD 1,223.6 billion |
Growth Rate | CAGR of 9.05% from 2022 to 2030 |
By Type |
|
By Application |
|
By Companies |
|
Regional Scope |
|
Reasons to Purchase this Report and Customization Scope |
|
Conclusion:
In conclusion, the hospital injectable drugs market is witnessing substantial growth and plays a critical role in delivering effective treatments for a wide range of medical conditions. The therapeutic diversity, technological advancements, and regulatory landscape within the market contribute to the improvement of patient care in hospital settings. With ongoing innovation and market expansion, the future of the hospital injectable drugs market holds promising opportunities for pharmaceutical companies and healthcare providers.
Crucial Points from this Hospital Injectable Drugs Market Report
The Hospital Injectable Drugs Market is growing at a CAGR of 9.05% During Forecast Period.
Generic Sterile Injectables,u00a0Sterile Intravenous (IV) Solutions
Hospital Pharmacy, Retail Pharmacy, E-commerceu00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0
Baxter International Inc., Sanofi, Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Gilead, and others.
The Hospital Injectable Drugs Market is growing at a CAGR of 9.05% During Forecast Period.
Generic Sterile Injectables,u00a0Sterile Intravenous (IV) Solutions
Hospital Pharmacy, Retail Pharmacy, E-commerceu00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0
Baxter International Inc., Sanofi, Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Gilead, and others.